Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karsten Nysom

Showing results (51-60 of 82) with videos related to

Pageof 9
Sort By:
JAMA Oncology|October 26, 2023
Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled TrialAndreas Peyrl, Monika Chocholous, Magnus Sabel, et al.
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|July 11, 2025
Glucocorticoid use in paediatric posterior fossa tumour surgery and the occurrence of postoperative speech impairmentRebekka Sarup, Aske F Laustsen, Martin K Sørensen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2023
Combination Early-Phase Trials of Anticancer Agents in Children and AdolescentsLucas Moreno, Steven G DuBois, Julia Glade Bender, et al.
Hemasphere|November 3, 2025
Isatuximab in combination with chemotherapy for pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia: The ISAKIDS studyAndré Baruchel, Karsten Nysom, Hyoung Jin Kang, et al.
British Journal of Cancer|February 12, 2026
Paediatric Therapeutic Development Workshop on rhabdoid tumoursClaudia Montiel Equihua, Jan J Molenaar, Itziar Areso, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2020
Clinical and genetic risk factors define two risk groups of extracranial malignant rhabdoid tumours (eMRT/RTK)Karolina Nemes, Susanne Bens, Denis Kachanov, et al.
Clinical Pharmacokinetics|June 22, 2024
Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059Jen-Hao Wu, Edoardo Pennesi, Francisco Bautista, et al.
JCO Precision Oncology|January 15, 2026
Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder AnalysisSusanne A Gatz, Julia Glade-Bender, Andrew D J Pearson, et al.
Neuro-Oncology|December 1, 2021
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumorsFrançois Doz, Cornelis M van Tilburg, Birgit Geoerger, et al.
Neuro-Oncology|December 19, 2024
Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trialKarsten Nysom, Lindsay B Kilburn, Sarah E S Leary, et al.
Pageof 9

Showing results (51-60 of 82) with videos related to

Sort By:
Pageof 9
JAMA Oncology|October 26, 2023
Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled TrialAndreas Peyrl, Monika Chocholous, Magnus Sabel, et al.
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|July 11, 2025
Glucocorticoid use in paediatric posterior fossa tumour surgery and the occurrence of postoperative speech impairmentRebekka Sarup, Aske F Laustsen, Martin K Sørensen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2023
Combination Early-Phase Trials of Anticancer Agents in Children and AdolescentsLucas Moreno, Steven G DuBois, Julia Glade Bender, et al.
Hemasphere|November 3, 2025
Isatuximab in combination with chemotherapy for pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia: The ISAKIDS studyAndré Baruchel, Karsten Nysom, Hyoung Jin Kang, et al.
British Journal of Cancer|February 12, 2026
Paediatric Therapeutic Development Workshop on rhabdoid tumoursClaudia Montiel Equihua, Jan J Molenaar, Itziar Areso, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2020
Clinical and genetic risk factors define two risk groups of extracranial malignant rhabdoid tumours (eMRT/RTK)Karolina Nemes, Susanne Bens, Denis Kachanov, et al.
Clinical Pharmacokinetics|June 22, 2024
Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059Jen-Hao Wu, Edoardo Pennesi, Francisco Bautista, et al.
JCO Precision Oncology|January 15, 2026
Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder AnalysisSusanne A Gatz, Julia Glade-Bender, Andrew D J Pearson, et al.
Neuro-Oncology|December 1, 2021
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumorsFrançois Doz, Cornelis M van Tilburg, Birgit Geoerger, et al.
Neuro-Oncology|December 19, 2024
Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trialKarsten Nysom, Lindsay B Kilburn, Sarah E S Leary, et al.
Pageof 9